Patents Assigned to Merck
  • SUBSTITUTED 6-MEMBERED ARYL OR HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20210077511
    Abstract: present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: March 18, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, BRIAN T. CAMPBELL, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Use of compositions comprising dihydroxyacetone for the protection of skin or hair against infrared irradiation
    Publication number: 20210077370
    Abstract: The non-therapeutical, cosmetic use of dihydroxyacetone in a cosmetic composition to be applied on skin, scalp, or hair for the protection of skin, scalp, or hair against infrared irradiation as well as the use of a cosmetic composition containing dihydroxyacetone as an agent for controlling tropoelastin expression in living cells of the epidermis and papillary dermis or as an agent for controlling the degradation of extracellular matrix components in living cells of the epidermis and papillary dermis, and dihydroxyacetone as an active ingredient to protect skin, scalp, or hair against damages after infrared irradiation by reacting with the skin, scalp, or hair or by penetrating the skin, scalp, or hair.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Applicant: Merck Patent GmbH
    Inventors: Valerie BICARD-BENHAMOU, Lilia HEIDER, Marina LEFORT, Jutta ZUR LAGE
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947213
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • Oxazolidinone compounds and methods of use thereof as antibacterial agents
    Patent number: 10947205
    Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947214
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • Process for producing recombinant trypsin
    Patent number: 10947521
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 16, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile
  • Formulation of an organic functional material
    Patent number: 10950792
    Abstract: The present invention relates to a formulation containing at least one organic functional material and at least two different organic solvents, a first organic solvent A and a second organic solvent B, wherein the first organic solvent A has a boiling point in the range from 250 to 350° C. and a viscosity of >15 mPas, the second organic solvent B has a boiling point in the range from 200 to 350° C. and a viscosity of ?10 mPas, the solubility of the at least one organic functional material in the second organic solvent B is ?5 g/l, and the boiling point of the first organic solvent A is at least 10° C. higher than the boiling point of the second organic solvent B; as well as to electroluminescent devices prepared by using these formulations.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Gaëlle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Manuel Hamburger, Anja Jatsch
  • Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
    Patent number: 10947222
    Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Thomas H. Graham, Jinlong Jiang, Fa-Xiang Ding, Clare Tudge
  • Organic electroluminescent element, display device, lighting device, PI-conjugated compound, and light-emitting thin film
    Patent number: 10950799
    Abstract: An object of the present invention is to provide an organic electroluminescent element containing an organic layer interposed between an anode and a cathode, the organic layer containing at least one light emitting layer, wherein the at least one light emitting layer contains a ?-conjugated compound having an electron donor portion and an electron acceptor portion in the molecule; the ?-conjugated compound has a direction vector from an atom having a HOMO orbital in the electron donor portion to an electron cloud of the HOMO orbital, and a direction vector from an atom having a LUMO orbital in the electron acceptor portion to an electron cloud of the LUMO orbital, and the two direction vectors form an angle ? in the range of 90 to 180 degrees; and the ?-conjugated compound has a plurality of the electron donor portions or a plurality of the electron acceptor portions.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Yasuo Miyata, Taketo Namikawa, Hiroshi Kita
  • PRMT5 inhibitors
    Patent number: 10947234
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, Michael D. Altman, Paul Anthony Stupple
  • Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 10945771
    Abstract: The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dane James Clausen, James I. Fells, Joseph A. Kozlowski, Ping Liu, Robert D. Mazzola, Jr.
  • Combination of a PD-1 antagonist and eribulin for treating cancer
    Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
  • SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20210070745
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Application
    Filed: April 29, 2019
    Publication date: March 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Harry R. Chobanian, James I. Fells, Deodial G. Guiadeen, Thomas J. Greshock, Kenneth J. Leavitt, Vanessa L. Rada, Ian M. Bell
  • LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY
    Publication number: 20210071081
    Abstract: The invention relates to a compound of formula I, wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention. The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.
    Type: Application
    Filed: April 18, 2019
    Publication date: March 11, 2021
    Applicant: Merck Patent GmbH
    Inventors: Lars LIETZAU, Simon SIEMIANOWSKI, Izumi SAITO
  • Materials for organic electroluminescent devices
    Patent number: 10944056
    Abstract: The present invention relates to spirobifluorene compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: March 9, 2021
    Assignee: Merck Patent GmbH
    Inventors: Elvira Montenegro, Amir H. Parham, Philipp Stoessel, Teresa Mujica-Fernaud, Frank Voges, Arne Buesing
  • Intermediates in the synthesis of cephalosporin compounds
    Patent number: 10941161
    Abstract: Described herein are crystalline forms of a compound of formula (III?), including toluene solvates of TATD-CLE, as well as processes for the preparation thereof and use thereof in the preparation of cephalosporin compounds such as ceftolozane.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 9, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Giovanni Fogliato, Manuel Scanu, You Seok Hwang
  • Compounds and organic electronic devices
    Patent number: 10944058
    Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 9, 2021
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Amir Hossain Parham, Arne Buesing, Frank Voges
  • DIELECTRIC MATERIALS
    Publication number: 20210062091
    Abstract: The present invention relates to a novel class of polymers which can be used as dielectric material for the preparation of passivation layers in electronic devices. The polymers are prepared from polymerizable compounds having mesogenic groups and they provide excellent film forming capability and excellent mechanical properties and have a low dielectric constant and a low coefficient of thermal expansion (CTE). There is further provided a method for forming said polymers and an electronic device containing said polymers as dielectric material. Beyond that, the present invention relates to a manufacturing method for preparing a packaged microelectronic structure and to a microelectronic device comprising said packaged microelectronic structure formed by said manufacturing method.
    Type: Application
    Filed: January 21, 2019
    Publication date: March 4, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Frank MEYER, Gregor LARBIG, Karsten KOPPE
  • FRAME FOR HOLDING FILTRATION ASSEMBLIES AND TESTING UNIT FOR MICROBIOLOGICAL TESTING
    Publication number: 20210060569
    Abstract: The invention concerns a frame (1) for holding a plurality of filtration assemblies (100) and a testing unit (10) for microbiological testing. The frame (1) for holding the plurality of filtration assemblies (100) comprises an array of supports (5) each configured to receive and support one of the filtration assemblies (100) on a common support plane (2), and connection means (6) provided on the periphery (7) of the frame (1) and configured to releasably connect, by a form-locking engagement, a further frame (1) such that the common support planes (2) of the connected frames (1) are contiguous. Further, the testing unit (10) comprises at least one frame (1) packed in a bag (20) in pre-sterilized condition.
    Type: Application
    Filed: September 4, 2018
    Publication date: March 4, 2021
    Applicant: Merck Patent GmbH
    Inventors: Philippe RIVAT, Mathieu ARRAULT
  • OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS
    Publication number: 20210061777
    Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Application
    Filed: November 10, 2020
    Publication date: March 4, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You